Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.43 -1.2%	$3.34	$2.71 ▼ $4.73	$656.95M	1.23	956,897 shs	1.02 million shs
ANAB AnaptysBio	$23.17 -0.9%	$21.29	$12.21 ▼ $41.31	$680.74M	-0.26	635,836 shs	454,361 shs
IKT Inhibikase Therapeutics	$1.66 -2.4%	$1.99	$1.12 ▼ $4.20	$123.41M	0.94	242,650 shs	278,054 shs
KALV KalVista Pharmaceuticals	$12.15 -1.3%	$12.50	$7.30 ▼ $15.50	$604.10M	-0.01	464,074 shs	1.36 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-2.83%	+6.52%	+1.18%	+12.46%
ANAB AnaptysBio	0.00%	-0.64%	+13.36%	+23.84%	-3.46%
IKT Inhibikase Therapeutics	0.00%	-10.75%	-6.21%	-29.96%	+18.57%
KALV KalVista Pharmaceuticals	0.00%	-6.25%	+5.93%	-0.82%	+3.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.4969 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.6
ANAB AnaptysBio	2.0787 of 5 stars	3.4	0.0	0.0	3.7	1.7	0.6
IKT Inhibikase Therapeutics	1.4768 of 5 stars	3.3	1.0	0.0	0.0	0.0	1.3
KALV KalVista Pharmaceuticals	3.827 of 5 stars	3.6	0.0	4.4	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	60.35% Upside
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	82.89% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	291.57% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	104.39% Upside

Current Analyst Ratings Breakdown

Latest IKT, ANAB, KALV, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/26/2025	ANAB AnaptysBio	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	106.47	N/A	N/A	$0.51 per share	6.73
ANAB AnaptysBio	$91.28M	7.46	N/A	N/A	$2.33 per share	9.94
IKT Inhibikase Therapeutics	$260K	474.65	N/A	N/A	$1.78 per share	0.93
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)

Latest IKT, ANAB, KALV, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
ANAB AnaptysBio	N/A	8.25	8.25
IKT Inhibikase Therapeutics	N/A	0.85	0.85
KALV KalVista Pharmaceuticals	N/A	10.44	10.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ANAB AnaptysBio	N/A
IKT Inhibikase Therapeutics	3.81%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ANAB AnaptysBio	33.50%
IKT Inhibikase Therapeutics	7.30%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable

IKT, ANAB, KALV, and ABUS Headlines

Recent News About These Companies

How KalVista Pharma Is Taking On A Rare But Deadly Disease

June 20 at 10:06 AM | msn.com

FDA delays decision on hereditary disease drug

June 18, 2025 | beckershospitalreview.com

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down - What's Next?

June 16, 2025 | marketbeat.com

Makary Considers More Cuts at FDA Amid Continued Delays

June 16, 2025 | biospace.com

FDA Plans to Shrink; Nursing Shortage at Walter Reed; Pelvic Floor Therapy for Men?

June 16, 2025 | medpagetoday.com

DOGE cuts cause FDA to delay decision on hereditary disease drug

June 16, 2025 | msn.com

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

June 16, 2025 | biopharmadive.com

KalVista Pharmaceuticals Shares Edge Down on FDA Delays for Sebetralstat Application

June 16, 2025 | marketwatch.com

FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision

June 16, 2025 | fiercebiotech.com

FDA won’t meet PDUFA goal date for sebetralstat

June 14, 2025 | thepharmaletter.com

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision

June 13, 2025 | bloomberg.com

DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints

June 13, 2025 | cantechletter.com

KalVista said FDA will not meet review date for sebetralstat

June 13, 2025 | msn.com

Health Sector Updates: Breakthroughs and Challenges

June 13, 2025 | devdiscourse.com

KalVista Pharmaceuticals Hit by FDA Delays

June 13, 2025 | marketwatch.com

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

June 13, 2025 | reuters.com

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

June 13, 2025 | businesswire.com

Cantor Fitzgerald Comments on KALV FY2026 Earnings

June 11, 2025 | marketbeat.com

Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 7,169 Shares of Stock

June 11, 2025 | insidertrades.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 7,169 Shares

June 10, 2025 | marketbeat.com

Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, ANAB, KALV, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.43 -0.04 (-1.15%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.47 +0.04 (+1.28%)

As of 07:05 AM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

AnaptysBio NASDAQ:ANAB

$23.17 -0.22 (-0.94%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.16 -0.01 (-0.02%)

As of 06/20/2025 06:07 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Inhibikase Therapeutics NYSE:IKT

$1.66 -0.04 (-2.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.01 (+0.60%)

As of 06/20/2025 05:23 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

KalVista Pharmaceuticals NASDAQ:KALV

$12.15 -0.16 (-1.30%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.40 +0.24 (+2.02%)

As of 07:44 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time